Drug Profile
Beclometasone/formoterol/glycopyrronium - Chiesi Farmaceutici
Alternative Names: Beclometasone dipropionate anhydrous/formoterol fumarate dihydrate/glycopyrronium bromide - Chiesi Farmaceutici; CHF 5993 DPI; CHF 5993 pMDI; CHF-5993; TrydonisLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Chiesi Farmaceutici
- Developer Chiesi Farmaceutici; Chiesi USA
- Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
- Phase III Asthma
Most Recent Events
- 13 Nov 2023 Phase-III clinical trials in Asthma in United Kingdom, Serbia, Georgia and Armenia (Inhalation) (ISRCTN17142179) (NCT06264674) (EudraCT2023-503333-22-00)
- 13 Oct 2023 Chiesi Farmaceutici completes a phase I trial for Asthma (In volunteers) in USA (Inhalation) (NCT05830071)
- 24 Apr 2023 Phase-I clinical trials in Asthma in Belgium (Inhalation) (NCT05898984)